Skip to main content

diamorphine hydrochloride (Ayendi®)

 

Following a limited submission

AWMSG advice

Status: Recommended

Diamorphine hydrochloride (Ayendi®) is recommended as an option for use within NHS Wales for the treatment of acute severe nociceptive pain in children and adolescents 2 to 15 years of age in a hospital setting. Ayendi® nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with the appropriate monitoring.

 Final Appraisal Recommendation (FAR): diamorphine hydrochloride (Ayendi) 2406 (PDF, 189Kb)
 AWMSG Secretariat Appraisal Report (ASAR): diamorphine hydrochloride (Ayendi)2406 (PDF, 80Kb)

Medicine details

Medicine name diamorphine hydrochloride (Ayendi®)
Formulation 720 micrograms nasal spray and 1600 micrograms nasal spray
Reference number 2406
Indication

Treatment of acute severe nociceptive pain in children and adolescents 2 to 15 years of age in a hospital setting. Diamorphine hydrochloride nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring

Company Wockhardt UK Ltd
BNF chapter Central nervous system
Submission type Limited
Status Recommended
Advice number 1719
NMG meeting date 09/10/2019
AWMSG meeting date 13/11/2019
Date of issue 28/11/2019